These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 23710205)

  • 21. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study.
    Castells L; Rimola A; Manzardo C; Valdivieso A; Montero JL; Barcena R; Abradelo M; Xiol X; Aguilera V; Salcedo M; Rodriguez M; Bernal C; Suarez F; Antela A; Olivares S; Del Campo S; Laguno M; Fernandez JR; de la Rosa G; Agüero F; Perez I; González-García J; Esteban-Mur JI; Miro JM;
    J Hepatol; 2015 Jan; 62(1):92-100. PubMed ID: 25127748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of HCV in renal transplant patients with peginterferon and ribavirin: long-term follow-up.
    Mak SK; Sin HK; Lo KY; Lo MW; Chan SF; Lo KC; Wong YY; Ho LY; Wong PN; Wong AKM
    Clin Exp Nephrol; 2017 Oct; 21(5):764-770. PubMed ID: 28083764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation.
    Everson GT; Terrault NA; Lok AS; Rodrigo del R; Brown RS; Saab S; Shiffman ML; Al-Osaimi AM; Kulik LM; Gillespie BW; Everhart JE;
    Hepatology; 2013 May; 57(5):1752-62. PubMed ID: 22821361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Twelve-week posttreatment follow-up to predict sustained virologic response for recurrent hepatitis C infection in liver recipients.
    Campos-Varela I; Castells L; Esteban JI; Bes M; Rodríguez-Frías F; Sapisochin G; Allende H; Charco R; Esteban R
    Transplantation; 2012 Feb; 93(4):450-3. PubMed ID: 22262129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Individualized extension of pegylated interferon plus ribavirin therapy for recurrent hepatitis C genotype 1b after living-donor liver transplantation.
    Ueda Y; Takada Y; Marusawa H; Egawa H; Uemoto S; Chiba T
    Transplantation; 2010 Sep; 90(6):661-5. PubMed ID: 20110853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiviral prophylactic intervention for chronic hepatitis C virus in patients undergoing liver transplantation.
    Gurusamy KS; Tsochatzis E; Davidson BR; Burroughs AK
    Cochrane Database Syst Rev; 2010 Dec; (12):CD006573. PubMed ID: 21154370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis C virus treatment pre- and post-liver transplantation.
    Roche B; Samuel D
    Liver Int; 2012 Feb; 32 Suppl 1():120-8. PubMed ID: 22212582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peg-IFN and ribavirin treatment for recurrence of genotype 2 and 3 hepatitis C after liver transplantation.
    Ackefors M; Castedal M; Dahlgard O; Verbaan H; Gjertsen H; Wernerson A; Weiland O
    Infect Dis (Lond); 2015 Apr; 47(4):209-17. PubMed ID: 25650729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.
    Alsaran K; Sabry A; Shaheen N
    Int Urol Nephrol; 2011 Sep; 43(3):865-73. PubMed ID: 20490669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [HCV entry as a new therapeutic target in chronic hepatitis C].
    Dabrowska MM; Panasiuk A; Flisiak R
    Pol Merkur Lekarski; 2009 Aug; 27(158):140-3. PubMed ID: 19856882
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation.
    Mukherjee S; Rogge J; Weaver L; Schafer DF
    Transplant Proc; 2003 Dec; 35(8):3042-4. PubMed ID: 14697974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pegylated interferon plus ribavirin combination therapy in postliver transplant recipients with recurrent hepatitis C virus infection.
    Lin TY; Yeh ML; Huang CI; Chen YL; Dai CY; Huang JF; Lin ZY; Chen SC; Huang CF; Yu ML; Chuang WL
    Kaohsiung J Med Sci; 2017 Jun; 33(6):284-289. PubMed ID: 28601232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testing.
    Neff GW; O'Brien CB; Cirocco R; Montalbano M; de Medina M; Ruiz P; Khaled AS; Bejarano PA; Safdar K; Hill MA; Tzakis AG; Schiff ER
    Liver Transpl; 2004 May; 10(5):595-8. PubMed ID: 15108250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.
    Samuel D; Bizollon T; Feray C; Roche B; Ahmed SN; Lemonnier C; Cohard M; Reynes M; Chevallier M; Ducerf C; Baulieux J; Geffner M; Albrecht JK; Bismuth H; Trepo C
    Gastroenterology; 2003 Mar; 124(3):642-50. PubMed ID: 12612903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current management and perspectives for HCV recurrence after liver transplantation.
    Coilly A; Roche B; Samuel D
    Liver Int; 2013 Feb; 33 Suppl 1():56-62. PubMed ID: 23286847
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of pegylated interferon and ribavirin combination therapy for patients with hepatitis C virus infection after curative resection or ablation for hepatocellular carcinoma--A retrospective multicenter study.
    Harada N; Hiramatsu N; Oze T; Tatsumi T; Hayashi N; Takehara T
    J Med Virol; 2015 Jul; 87(7):1199-206. PubMed ID: 25772024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Controversies in the management of hepatitis C virus infection after liver transplantation.
    Shiffman ML; Vargas HE; Everson GT
    Liver Transpl; 2003 Nov; 9(11):1129-44. PubMed ID: 14586872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of genotype 4 hepatitis C recurring after liver transplantation using a combination of pegylated interferon alfa-2a and ribavirin.
    Al-Hamoudi W; Mohamed H; Abaalkhail F; Kamel Y; Al-Masri N; Allam N; Alqahtani S; Al-Sofayan M; Khalaf H; Al-Sebayel M; Al-Jedai A; Abdo A
    Dig Dis Sci; 2011 Jun; 56(6):1848-52. PubMed ID: 21221800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin.
    Selvapatt N; Habibi MS; Brown A
    J Med Virol; 2015 Oct; 87(10):1716-21. PubMed ID: 25914248
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines.
    European Association of the Study of the Liver
    Liver Int; 2012 Feb; 32 Suppl 1():2-8. PubMed ID: 22212565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.